## SD181004-002 page 1 of 1

PharmLabs San Diego Certificate of Analysis

## **Sample Super Silver Haze**





Sample ID SD181004-002 (32301) Tested for CaliBloom Matrix Flower (Inhalable Cannabis Good) Received Oct 04, 2018 Reported Oct 04, 2018 Sampled -Analyses executed CAN

## \* CAN - Cannabinoids Analysis Analyzed Oct 04, 2018 | Instrument HPLC-VWD | Method SOP-001 The expanded Uncertainty of the Cannabinoid analysis is approximately **J**.806% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g
Cannabidiolic Acid (CBDA)	0.001	0.16	0.04	0.40
Cannabigerol (CBG)	0.001	0.16	0.12	1.20
Cannabidiol (CBD)	0.001	0.16	ND	ND
Cannabinol (CBN)	0.001	0.16	0.12	1.20
Tetrahydrocannabinol (Δ9-THC)	0.003	0.16	3.54	35.40
Δ8-tetrahydrocannabinol (Δ8-THC)	0.004	0.16	NT	NT
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.16	NT	NT
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.16	NT	NT
Tetrahydrocannabinolic Acid (THCA)	0.001	0.16	18.67	186.70
Total THC ( THCa * 0.877 + Δ9THC )			19.91	199.14
Total CBD ( CBDa * 0.877 + CBD )			0.04	0.35
Total Cannabinoids Analyzed			20.19	201.89
				*Dru Woigh

\*Dry Weight %



Pharm//are CANNABIS LABORATORY LIMS & ELN



DCC license: C8-0000098-LIC DEA license: RP0611043 ISO/IEC 17025:2017 Acc. L17-427-1



This Certificate of Analysis has not been finalized and it represents a draft until electronically signed

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1 This report shall got be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to plagnage, treat or prevent any disease. Results are only for samples and batches indicated. Results or reported on an os received bas, onlies indicated on therwise. When a disease the start is to report the advectional purposes only and should not be used to plagnage, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an os received bas, onlies indicated on therwise. When a disease, the start is to report and the contract is to related to be in compliance. The measurement of uncertainty is not included in the Pass/Fail start is referred. Start and local lows which are required to the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail start is referred. Start and local lows which are required to the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail start is referred. Start and local lows which are required to the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail start is referred. Start and local lows with hore the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail start is referred. Start and local lows on the start is not included in the customer to be in compliance. The measurement of uncertainty is not included in the pass/Fail start is not included in the customer to be in compliance. The measurement of uncertainty is not included in the pass/Fail start is not included in the customer to be in compliance. The measurement of uncertainty is not included in the pass/Fail start is not included in the start is not included in the start is not included in the customer to be in compliance. The measurement of uncertainty is not included in the pass/Fail start is not included in the start is not included in the customer to be in